Foo M L, Gunderson L L, Nagorney D M, McLlrath D C, van Heerden J A, Robinow J S, Kvols L K, Garton G R, Martenson J A, Cha S S
Division of Radiation Oncology, Mayo Clinic, Rochester, MN.
Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9. doi: 10.1016/0360-3016(93)90967-z.
Analyze patterns of failure, survival, and tolerance in patients with totally resected ductal adenocarcinoma of the pancreas treated with adjuvant irradiation alone or combined with chemotherapy.
The records of 29 patients treated with radiotherapy following curative resection of pancreas cancer at the Mayo Clinic were retrospectively reviewed. Twenty-two (76%) patients underwent a subtotal pancreatectomy (Whipple procedure), six (21%) a total pancreatectomy, and one (3.5%) a distal pancreatectomy. Twenty-six (90%) had lesions located in the head of the pancreas and three (10%) were located either in the body or tail. Twelve (41%) of the tumors were histologic Grade 3, 15 (52%) Grade 2, and two Grade 1. Contiguous invasion of adjacent tissues or organs was found in fifteen patients (52%) and seventeen (59%) had lymph node involvement. Greater than 75% of patients received more than 45 Gy, with a median dose of 54 Gy, and twenty-seven (93%) patients received concomitant 5-fluorouracil chemotherapy.
The median survival was 22.8 months and the 2-year survival 48%. When survival was compared with that achieved with surgery alone in our institution, data suggested a doubling in both median and long-term survival with the addition of adjuvant treatment. Eighty-three percent of patients experienced tumor relapse with seventeen of 29 (59%) developing either liver metastases or peritoneal spread. In three patients, tumors recurred locally; one of one with microscopic residual disease after resection and two of 28 (7%) with negative margins (one of the two was treated with inadequate radiation portals). Patients tolerated adjuvant treatment with minimal acute toxicity consisting mostly of vomiting or nausea which, were controlled with medication in all patients. Chronic toxicity was acceptable; while 5 of 29 (17%) developed some form of possible treatment related complication, only one patient (3.5%) developed a small bowel obstruction.
These results corroborate data in previous studies which have shown a survival benefit when adjuvant irradiation plus 5-fluorouracil is used in patients with completely resected ductal adenocarcinoma of the pancreas. The patterns of failure indicate that post-operative adjuvant treatment can effectively control disease locally but that future survival improvements will be achieved only by reducing the incidence of liver and peritoneal metastases.
分析单纯接受辅助放疗或联合化疗的胰腺导管腺癌全切术后患者的失败模式、生存率和耐受性。
回顾性分析梅奥诊所29例胰腺癌根治性切除术后接受放疗患者的记录。22例(76%)患者接受了胰头次全切除术(惠普尔手术),6例(21%)接受了全胰切除术,1例(3.5%)接受了胰体尾切除术。26例(90%)患者的病变位于胰头,3例(10%)位于胰体或胰尾。12例(41%)肿瘤组织学分级为3级,15例(52%)为2级,2例为1级。15例(52%)患者发现相邻组织或器官有连续性侵犯,17例(59%)有淋巴结转移。超过75%的患者接受了超过45 Gy的放疗,中位剂量为54 Gy,27例(93%)患者同时接受了5-氟尿嘧啶化疗。
中位生存期为22.8个月,2年生存率为48%。将本机构的生存率与单纯手术治疗的生存率进行比较时,数据表明辅助治疗使中位生存期和长期生存率均提高了一倍。83%的患者出现肿瘤复发,29例中有17例(59%)发生肝转移或腹膜播散。3例患者肿瘤局部复发;1例为切除术后有微小残留病灶的患者,28例切缘阴性的患者中有2例(7%)(2例中的1例放疗野设置不当)。患者对辅助治疗的耐受性良好,急性毒性最小,主要为呕吐或恶心,所有患者均通过药物控制。慢性毒性可以接受;29例中有5例(17%)出现某种形式的可能与治疗相关的并发症,只有1例患者(3.5%)发生小肠梗阻。
这些结果证实了既往研究的数据,即对于胰腺导管腺癌全切术后患者采用辅助放疗加5-氟尿嘧啶治疗可提高生存率。失败模式表明,术后辅助治疗可有效控制局部疾病,但未来生存率的提高只能通过降低肝转移和腹膜转移的发生率来实现。